Related Experiment Video

Updated: Jul 13, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

Use of octreotide acetate to prevent rebound hypoglycaemia in sulfonylurea overdose

Ziauddin Hassan1, John Wright

  • 1Registrar in Emergency Medicine, Newcastle General Hospital, Newcastle, UK.

Emergency Medicine Journal : EMJ
|July 27, 2007
PubMed

Insights

Octreotide may effectively prevent rebound hypoglycemia following sulfonylurea overdose. This review suggests octreotide is a potentially safe and effective treatment option for managing this specific overdose complication.

Area of Science:

  • Clinical Pharmacology
  • Toxicology
  • Endocrinology

Background:

  • Sulfonylurea medications are commonly prescribed for type 2 diabetes.
  • Overdose of sulfonylureas can lead to prolonged and severe hypoglycemia.
  • Rebound hypoglycemia can occur hours after initial treatment, posing a significant clinical challenge.

Purpose of the Study:

  • To evaluate the efficacy and safety of octreotide in preventing rebound hypoglycemia after sulfonylurea overdose.
  • To synthesize the best available evidence regarding octreotide's role in managing sulfonylurea-induced hypoglycemia.

Main Methods:

  • A focused literature search was conducted to identify relevant studies.
  • A critical review of fourteen identified papers was performed.
  • Two papers providing the strongest evidence were selected for detailed analysis.

Main Results:

  • The review identified limited high-quality evidence, with two key papers analyzed.
  • Analysis focused on patient groups, study design, outcomes, and results.
  • Weaknesses of the included studies were also considered.

Conclusions:

  • Octreotide demonstrates potential as a safe and effective agent for preventing rebound hypoglycemia post-sulfonylurea overdose.
  • Further research may be warranted to confirm these findings in larger or more diverse patient populations.

Related Concept Videos

Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...